Aprea Therapeutics Raises $5.6M in At-The-Market Private Placement
Event summary
- Aprea Therapeutics raised $5.6M through a private placement of 6.3M shares of common stock and warrants, priced at $0.89 per share.
- Proceeds will be used for general corporate purposes and R&D expenses, particularly to backfill patients in the ACESOT-1 dose-escalation study for APR-1051.
- The offering is expected to close on January 30, 2026, subject to customary closing conditions.
- Warrants issued have an exercise price of $0.765 per share and are exercisable immediately, expiring on the two-year anniversary of the registration statement's effectiveness.
The big picture
Aprea Therapeutics' $5.6M raise underscores the ongoing need for clinical-stage biopharmaceutical companies to secure non-dilutive financing to support pivotal trials. The focus on backfilling patients in the ACESOT-1 study highlights the strategic importance of dose optimization in advancing APR-1051 through development. This move comes amid a broader trend of biotech firms leveraging at-the-market offerings to extend runway without triggering immediate dilution.
What we're watching
- Clinical Progress
- How the additional funding will accelerate patient enrollment and dose optimization in the ACESOT-1 study.
- Financial Stability
- Whether the $5.6M raise will provide sufficient runway for Aprea to reach key clinical milestones.
- Market Positioning
- The pace at which Aprea can differentiate APR-1051 in the competitive WEE1 kinase inhibitor space.
Related topics